IL23A and Cowden disease: To address this question, we interrogated transcriptomic, serological and clinical data from a large cohort of patients with active colonic CD from the UNITI study, a large phase III trial programme evaluating the efficacy of ustekinumab, a human IgG1κ mAb targeting the p40 subunit common to both IL12 and IL23.30 Colonic biopsies were sampled at baseline (ie, before administration of the study drug) and longitudinally following initiation of drug.